|
21 Nov 2021 |
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
|
|
21 Nov 2021 |
Akston Biosciences Doses First Subjects in Phase II Clinical Trial in India of Second-Generation COVID-19 Vaccine
|
|
17 Nov 2021 |
Daiichi Sankyo Initiates Phase 2 Trial of mRNA Vaccine Against COVID-19 (DS-5670) in Japan
|
|
16 Nov 2021 |
Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate
|
|
14 Nov 2021 |
AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer’s Vaccine Generates a Potent Immune Response
|
|
12 Nov 2021 |
Recbio Announces Promising Preliminary Results From First-in-Human Study of a COVID-19 Vaccine Candidate With Novel Adjuvant BFA03
|
|
11 Nov 2021 |
Inventprise Announces Investment of up to $90 Million to Advance its 25 Valent Pneumococcal Conjugate Vaccine Candidate into Proof-of-Concept Clinical Trials
|
|
10 Nov 2021 |
Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2
|
|
05 Nov 2021 |
Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years
|
|
04 Nov 2021 |
Uvax-2129, a Recombinant Protein Nanoparticle Vaccine, Uvax Bio’s Answer to COVID-19, Shows Great Promise Against Variants of Concern
|
|
01 Nov 2021 |
Novavax Files for COVID-19 Vaccine Authorization with Health Canada and Completes Submission for Rolling Review to European Medicines Agency
|
|
30 Oct 2021 |
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
|
|
29 Oct 2021 |
First patient recruited into Alzinova's phase 1b clinical study with the oligomer-specific ALZ-101 vaccine against Alzheimer's disease
|
|
28 Oct 2021 |
Meissa Announces Positive Preliminary Clinical Data on Safety and Immunogenicity of Intranasal COVID-19 Vaccine
|
|
27 Oct 2021 |
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
|
|
27 Oct 2021 |
Provention Bio Announces Positive Interim Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
|
|
27 Oct 2021 |
Vaxart Doses First Subject in Phase II COVID-19 Oral Tablet Vaccine Clinical Trial
|
|
27 Oct 2021 |
Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study
|
|
27 Oct 2021 |
Moderna Announces First Participant Dosed in Phase 3 Pivotal Registration Study of Its mRNA Cytomegalovirus (CMV) Vaccine
|
|
25 Oct 2021 |
Kiromic BioPharma, Now Clinical Stage, Reports Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax/BSK01, Company’s Phase 1 Cell Therapy Cancer Vaccine Candidate for Solid Tumors
|
|
25 Oct 2021 |
Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age
|
|
21 Oct 2021 |
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
|
|
21 Oct 2021 |
Moderna Announces FDA Authorization of a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.
|
|
21 Oct 2021 |
Daiichi Sankyo Announces Development Progress of mRNA COVID-19 Vaccine in Japan
|
|
21 Oct 2021 |
Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
|
